Cargando…
Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis
Administration of bevacizumab to patients with brain metastases (BM) is controversial due to concerns about the increased risk of intracranial hemorrhage (ICH). This meta-analysis assessed whether the risk of ICH increases in BM patients receiving treatments that contain bevacizumab versus without....
Autores principales: | Yang, Lin, Chen, Chuan-Jie, Guo, Xiao-Ling, Wu, Xiao-Cui, Lv, Bo-Jie, Wang, Hong-Li, Guo, Zhi, Zhao, Xiang-Yang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846997/ https://www.ncbi.nlm.nih.gov/pubmed/29170906 http://dx.doi.org/10.1007/s11060-017-2693-4 |
Ejemplares similares
-
Prophylactic anticoagulation in patients with glioblastoma or brain metastases and atrial fibrillation: an increased risk for intracranial hemorrhage?
por: Burth, Sina, et al.
Publicado: (2021) -
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer
por: Bertolini, F, et al.
Publicado: (2011) -
Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases
por: De Bruyne, S, et al.
Publicado: (2012) -
Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial
por: Nasti, G, et al.
Publicado: (2013) -
Predicting response to radiotherapy of intracranial metastases with hyperpolarized [Formula: see text] C MRI
por: Lee, Casey Y., et al.
Publicado: (2021)